Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $145,041.52 in Stock

Key Points

• Insider sales: General Counsel Jonathan Allan sold 4,628 shares on March 18 for $145,041.52 and also sold 4,267 shares on March 17 for $140,853.67, reducing his holdings and totaling roughly $285,895 in sales over two days.
• Stock and analyst sentiment: STOK traded up about 7% to $33.19, with multiple firms issuing buy ratings (average price target ~$39.83 and high targets up to $60), reflecting bullish analyst interest despite volatility.
• Business outlook and risks: Stoke is a clinical‑stage biotech led by the STK‑001 program for Dravet syndrome (long‑term upside if trials succeed), but recent quarterly results missed expectations (EPS -$0.97 vs -$0.75; revenue $1.4M vs $5.3M expected), posing near‑term headwinds.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $145,041.52. Following the transaction, the general counsel owned 28,836 shares of the company's stock, valued at approximately $903,720.24. The trade was a 13.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, March 17th, Jonathan Allan sold 4,267 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total transaction of $140,853.67.

Stoke Therapeutics Trading Up 7.0%

Shares of STOK stock traded up $2.17 during trading hours on Thursday, hitting $33.19. The company's stock had a trading volume of 853,428 shares, compared to its average volume of 754,489. The business has a fifty day moving average of $32.61 and a 200-day moving average of $29.90. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $40.22. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Chardan Capital reissued a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. UBS Group set a $50.00 price objective on Stoke Therapeutics in a research report on Monday, December 15th. Guggenheim initiated coverage on Stoke Therapeutics in a research report on Thursday, February 5th. They set a "buy" rating and a $60.00 price objective for the company. Wolfe Research assumed coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They issued an "outperform" rating and a $40.00 target price for the company. Finally, Canaccord Genuity Group upped their target price on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a "buy" rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $39.83.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Principal Financial Group Inc. acquired a new stake in Stoke Therapeutics during the third quarter worth about $1,062,000. Marshall Wace LLP lifted its stake in shares of Stoke Therapeutics by 7.9% in the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company's stock valued at $26,111,000 after purchasing an additional 168,771 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at about $3,539,000. Franklin Resources Inc. grew its holdings in shares of Stoke Therapeutics by 264.8% during the 2nd quarter. Franklin Resources Inc. now owns 81,395 shares of the company's stock worth $924,000 after purchasing an additional 59,081 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company's stock worth $74,351,000 after purchasing an additional 217,616 shares during the period.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed "buy" with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.